Literature DB >> 32198150

Telomere Attrition in Childhood Cancer Survivors.

Kyle M Walsh1,2.   

Abstract

Childhood cancer survivors experience substantial treatment-related morbidity and biomarkers of long-term survivor health are needed. Leukocyte telomere length is shortened in childhood cancer survivors and associates with the occurrence of numerous chronic health conditions. Healthy lifestyle factors can attenuate telomere attrition in young-adult survivors, implicating critical windows for intervention.See related article by Song et al., p. 2362. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2020        PMID： 32198150     DOI： 10.1158/1078-0432.CCR-20-0380

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  3 in total

1.  Early life trauma and adult leucocyte telomere length.

Authors:  Jennifer M P Woo; Christine G Parks; Emily E Hyde; Paul L Auer; Amanda M Simanek; Rebecca H Konkel; Jack Taylor; Dale P Sandler; Helen C S Meier
Journal:  Psychoneuroendocrinology       Date:  2022-07-23       Impact factor: 4.693

2.  Genome-wide association studies identify novel genetic loci for epigenetic age acceleration among survivors of childhood cancer.

Authors:  Qian Dong; Nan Song; Na Qin; Cheng Chen; Zhenghong Li; Xiaojun Sun; John Easton; Heather Mulder; Emily Plyler; Geoffrey Neale; Emily Walker; Qian Li; Xiaotu Ma; Xiang Chen; I-Chan Huang; Yutaka Yasui; Kirsten K Ness; Jinghui Zhang; Melissa M Hudson; Leslie L Robison; Zhaoming Wang
Journal:  Genome Med       Date:  2022-03-22       Impact factor: 11.117

3.  Epigenetic Age Acceleration and Chronic Health Conditions Among Adult Survivors of Childhood Cancer.

Authors:  Na Qin; Zhenghong Li; Nan Song; Carmen L Wilson; John Easton; Heather Mulder; Emily Plyler; Geoffrey Neale; Emily Walker; Xin Zhou; Haitao Pan; Melissa M Hudson; Yutaka Yasui; Leslie L Robison; Jinghui Zhang; Kirsten K Ness; Zhaoming Wang
Journal:  J Natl Cancer Inst       Date:  2021-05-04       Impact factor: 13.506
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.